Art Pappas speaks on life sciences innovation at Biotech Showcase 2012
News | 01. 16. 2012
Life sciences innovation: The struggle to retain and attract investors
Biotech Showcase 2012 during the JP Morgan Healthcare Conference
January 11, 2012
San Francisco, CA
A recent study by the NVCA reported that many venture capitalists are eliminating their investments in US life science companies altogether while others are shifting their focus to ex-US investments principally because of perceived regulatory obstacles. Furthermore, with few exceptions, companies with early stage pipelines are not likely IPO candidates nor are they compelling targets for M&A transactions with big pharma. These trends paint a daunting picture for any life science company trying to advance their programs. This panel, with Roger Longman of Real Endpoints; Polly Murphy, Pfizer; Arthur Pappas of Pappas Ventures;Barbara Fox, Avaxia Biologics; Evonne Sepsis, ESC Advisors; and Todd Sherer of Michael J. Fox Foundation, led by moderator Ellen Corenswet of Covington & Burling, discusses potential ways to address these obstacles on multiple levels for innovator companies as well as their investors.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.